Key result
Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus was analyzed using data from the JPAD, POPADAD, and AAA trials.
Key points are not available for this paper at this time.
Reanalysis of trial data leaves open aspirin's role in primary prevention for PAD or diabetes; dedicated RCTs needed before practice change.
Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus - Analyses from the JPAD, POPADAD and AAA trials
No takes yet. Share an insight, caveat, or question.
Morimoto et al. (2010) studied this question. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus was analyzed using data from the JPAD, POPADAD, and AAA trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: